Back

Anonymous

Anonymous 4

Hey I am on Medial • 5m

As someone who actually used both Cepheid and Truenat systems during COVID (I work in hospital administration), there are significant differences. Cepheid is more user-friendly with fully integrated cartridges but costs 3-4x more per test. Truenat requires more manual steps but is much more cost-effective. In wealthy countries, Cepheid wins easily. In resource-limited settings, Truenat has a massive advantage. The question for investors is where the growth will come from. If Molbio stays focused on emerging markets, they could build a sustainable business. If they try to compete head-on with Cepheid in developed markets, they'll likely fail. Their valuation assumes they'll succeed everywhere, which is unrealistic.

1 Reply
3
Replies (1)

More like this

Recommendations from Medial

Image Description
Image Description

Nimesh Pinnamaneni

 • 

Helixworks Technologies • 5m

From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. šŸ’° Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. šŸ”¬ Their Truenat platform, is a battery-power

See More
10 Replies
15
40

Nimesh Pinnamaneni

 • 

Helixworks Technologies • 5m

Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren

See More
Reply
2
Image Description

Armaan Nath

Startups | Product • 11m

Today marks a very important day, I got rejected for giving an interview because currently my location is in tier-2 city.šŸ˜‚šŸ¤ŒšŸ» Man come on! That's unrealistic!

4 Replies
6
Image Description
Image Description

Mohit Mittal_KMC

Hey I am on Medial • 7m

Do a startup making incense sticks/cones from waste flowers would work in urban Markets? Considering the end product is 3-5x more expensive than the established incense stick manufacturers ?

2 Replies
4
Image Description

Chamarti Sreekar

Fcuk imposter syndro... • 6m

The Future is Being Built Right Now – And This is MASSIVE $20 billion. That’s the valuation Safe Superintelligence is now chasing—a 4X jump in just a few months. This isn’t just another AI startup raising capital. This is the birth of something monu

See More
1 Reply
19

Poosarla Sai Karthik

Tech guy with a busi... • 17d

MRF is a ₹61000 Cr heavyweight. It has dominated Indian tyres and cricket for decades. CEAT, at ₹15000 Cr, is a quarter of that. But it delivers similar profit margins (MRF: 6.5%, CEAT: 6.6%), comparable return on equity, and pays 4x more in dividen

See More
Reply
9
Image Description
Image Description

Chamarti Sreekar

Fcuk imposter syndro... • 26d

At WAIC 2025, Huawei unveiled CloudMatrix 384, a supercomputer powered by 384 Ascend 910C chips delivering 300 petaFLOPS — nearly 2x faster than Nvidia’s GB200 NVL72. But here's the catch: it consumes 4x more power This move is less about efficie

See More
2 Replies
4
1
Image Description

Mohit Kumar

Entrepreneur | App &... • 1y

How is Indian AR VR Markets ? Do you know any startups who are doing wonderful in VR Market?

1 Reply
2

Vivek Joshi

Director & CEO @ Exc... • 3m

My latest book along with Other Editors published by Springer. Book is now available in the markets globally. šŸ™šŸ½

Reply
2

Download the medial app to read full posts, comements and news.